Browsing by Author Lorigan, Paul

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 6 of 6
Issue DateTitleAuthor(s)Citation
2016Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapyCarlino, Matteo; Long, Georgina; Atkinson, Victoria; Bowyer, Samantha; et al, .; Khou, M.; Larkin, James; Lorigan, Paul; McArthur, Grant A.; Millward, Michael; Prithviraj, P.; Western Clinical School: Medicine (Westmead); Central Clinical School: The Sydney Cancer CentreEfficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy, British Journal of Cancer, vol.114, 10, 2016,pp 1084-1089
2015Pembrolizumab versus ipilimumab in advanced melanomaCarlino, Matteo; Long, Georgina; Arance, Ana; Daud, Adil; et al, Various; Grob, Jean Jacques; Larkin, James; Lorigan, Paul; Lotem, Michal; McNeil, Catriona; Mortier, Laurent; Neyns, Bart; Robert, Caroline; Schachter, Jacob; Western Clinical School: Medicine (Westmead); Central Clinical School: The Sydney Cancer CentrePembrolizumab versus ipilimumab in advanced melanoma, The New England Journal of Medicine, vol.372, 26, 2015,pp 2521-2532
2013Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanomaKefford, Richard (Rick); et al, Various; Garbe, Claus; Gogas, Helen; Haanen, John; Linette, Gerald; Lorigan, Paul; Marmol, Maribel; Marshall, Margaret A.; Punt, Cornelis J.A.; Ribas, Antoni; Schachter, Jacob; Western Clinical School: Westmead Millennium InstitutePhase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma, Journal of Clinical Oncology, vol.31, 5, 2013,pp 616-622
2014Surrogate endpoints for overall survival in metastatic melanoma: A meta-analysis of randomised controlled trialsKefford, Richard (Rick); Long, Georgina; Ascierto, Paolo; Dummer, R; Eggermont, Alexander; Flaherty, Keith; Hauschild, A; Hennig, Michael; Kirkwood, John; Lee, Sandra J; Lorigan, Paul; Mackensen, Andreas; McArthur, Grant A.; O'Day, Steven; Patel, Poulam; Robert, Caroline; Schadendorf, D; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreSurrogate endpoints for overall survival in metastatic melanoma: A meta-analysis of randomised controlled trials, The Lancet Oncology, vol.15, 3, 2014,pp 297-304
2016Survival of patients with advanced metastatic melanoma: The impact of novel therapiesLong, Georgina; Ascierto, Paolo; et al, Various; Flaherty, Keith; Grob, Jean-Jacques; Hauschild, Axel; Larkin, James; Lorigan, Paul; McArthur, Grant A.; Rohmel, Joachim; Ugurel, Selma; Northern Clinical School: MedicineSurvival of patients with advanced metastatic melanoma: The impact of novel therapies, European Journal of Cancer, vol.53, N/A, 2016,pp 125-134
2017Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017Long, Georgina; Ascierto, Paolo; et al, Various; Flaherty, Keith; Grob, Jean-Jacques; Hauschild, Axel; Larkin, James; Lorigan, Paul; McArthur, Grant A.; Rohmel, Joachim; Ugurel, Selma; Northern Clinical School: MedicineSurvival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017, European Journal of Cancer, vol.83, N/A, 2017,pp 247-257